Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A metabolic treatment for pancreatic cancer?

Pancreatic cancer is now the third leading cause of cancer mortality.

Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent.

Research led by Nada Kalaany, PhD, at Boston Children's Hospital and the Broad Institute of MIT and Harvard, now suggests a novel approach to treating this deadly cancer: targeting an enzyme that tumours use to get rid of nitrogen.

The study, published online in Nature Communications, provides evidence that targeting the enzyme arginase 2 (ARG2) can curb the growth of pancreatic tumours, especially in people who are obese.

The researchers began by introducing human pancreatic tumours into obese and lean mice.

They then analysed what genes the tumours turned on and what metabolic products they were producing.

They found that tumours in obese mice had enhanced expression of many genes involved in metabolising nitrogen, a natural byproduct of cells when proteins are broken down.

Until now, how nitrogen excess affects tumour growth has been largely unknown.

"We found that highly malignant pancreatic tumours are very dependent on the nitrogen metabolism pathway," says Kalaany, a researcher in Boston Children's Division of Endocrinology and an assistant professor at Harvard Medical School.

Curbing tumour growth by preventing nitrogen disposal

Pancreatic tumours grew faster in obese mice than in lean mice and produced increased amounts of ARG2, an enzyme that helps dispose of excess nitrogen by breaking down ammonia, as part of the urea cycle.

Kalaany and colleagues also analysed tumour samples removed from 92 patients with pancreatic cancer, through collaboration with Massachusetts General Hospital and the Dana-Farber Cancer Institute.

They showed that ARG2 levels in the tumours increased together with patients' body mass index (BMI).

When the researchers silenced or deleted ARG2 in the tumours of obese mice, nitrogen accumulated (in the form of ammonia) and pancreatic cancer growth was strongly suppressed.

"Pancreatic tumours are known to take up and break down large amounts of protein to fuel their growth," explains Kalaany. "They need ARG2 to get rid of the extra nitrogen and prevent ammonia from accumulating."

Not just the obese

Although pancreatic tumours grew more robustly in the obese mice and produced more ARG2, as did tumours from higher-BMI patients, tumours in lean mice appear to activate the same metabolic pathway.

"In a lean mouse model bearing fast-growing tumours, we saw the same transcriptomic signature that we did in the obese mice," says Kalaany. "It seems obesity or rapid growth exaggerate a tumour's need to get rid of nitrogen."

ARG2 is closely related to ARG1, the liver enzyme we ourselves use to rid our bodies of excess nitrogen.

In mouse models and in humans, deficiencies of ARG1 have been shown to cause neurological impairment, growth retardation and fatal ammonia toxicity.

But deleting the ARG2 gene does not appear to cause serious side effects, at least in mice.

"There could be a therapeutic window here," says Kalaany. The team plans to conduct chemical screens to identify inhibitors of arginase 2 that could potentially be used as drugs. Most known inhibitors also inhibit arginase 1, but at least one has action more specific to arginase 2, she says.

"Pancreatic cancer is notoriously resistant to conventional treatment options," said Julie Fleshman, JD, MBA, president and CEO at the Pancreatic Cancer Action Network, which helped fund this work. "The discovery of novel drug targets like ARG2 could have a significant impact on patient outcomes and move us closer to our goal to double pancreatic cancer survival by 2020."

Source: Boston Children's Hospital



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence